"To Study the Impact of Balloon-occluded Retrograde Transvenous Obliteration (BRTO)/Plug Assisted Retrograde Transvenous Obliteration (PARTO) Mediated Portal Flow Modulation in Reduction of Ammonia and Improvement in Organ Volume and Functionality in Patients of Cirrhosis With LR Shunt

NCT ID: NCT04089878

Last Updated: 2019-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-14

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The informed consent will be obtained from the participants in the study. The study will be conducted on indoor patients, Department of Hepatology ILBS, New Delhi. This will be a Pilot study (sample size 25 cases in each arm) with 50% chances of each patient to randomized into each arm(1:1 randomization) .

Study Population - Patients with hepatic encephalopathy with LR shunt admitted in wards/HDU (High Dependency Unit)/LC ICU(Liver Coma ICU).

Study design-Randomized controlled Trial

Study period- 1 year.

Sample Size-Single Centre prospective RCT

* Sample size- Pilot study (sample size 25 cases in each arm)
* Follow up duration-6 months

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cirrhoses

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PARTO/BRTO + SMT

PARTO/BRTO with SMT will be given.

Group Type EXPERIMENTAL

Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration

Intervention Type PROCEDURE

Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration

Standard Medical Treatment

Antibiotics, nutrition and supportive treatment

Group Type ACTIVE_COMPARATOR

Standard Medical Treatment

Intervention Type OTHER

Antibiotics, nutrition and supportive treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration

Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration

Intervention Type PROCEDURE

Standard Medical Treatment

Antibiotics, nutrition and supportive treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Child A and B cirrhotic patients with Gastro/lieno-renal shunt of \>8 mm.
* Covert or Overt HE
* Age 18 to 70 years

Exclusion Criteria

* Intractable ascites
* PVT (with 100 % block )or PV Cavernoma and splenic vein thrombosis
* High risk esophageal varices (till eradicated)
* HVPG \>16 mm Hg
* HCC
* Pregnancy and lactation
* Refusal to participate in the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institute of Liver and Biliary Sciences, India

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr Shiv Kumar Sarin, DM

Role: PRINCIPAL_INVESTIGATOR

Institute of Liver and Biliary Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Liver & Biliary Sciences

New Delhi, National Capital Territory of Delhi, India

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

India

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dr Shiv Kumar Sarin, DM

Role: CONTACT

01146300000

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dr Rakesh Kumar Jagdish, MD

Role: primary

01146300000

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ILBS-Cirrhosis-25

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.